- On Friday, cannabis product manufacturer HYTN Innovations (CSE:HYTN) signed supply agreements with two cultivators for a minimum of 4,000 kg of cannabis for the German market
- The agreements, signed in February 2025, involve Klonetics Plant Science and a Kelowna-based company under non-disclosure
- HYTN is a pharmaceutical company formulating and manufacturing products containing psychoactive and psychotropic compounds, including cannabis and psilocybe-derived tryptamines
- HYTN Innovations stock has added 61.11 per cent since announcing the supply agreements on March 28
On Friday, cannabis product manufacturer HYTN Innovations (CSE:HYTN) signed supply agreements with two cultivators for a minimum of 4,000 kg of cannabis for the German market.
The agreements, signed in February with Klonetics Plant Science and a Kelowna-based company under non-disclosure, come after HYTN’s comprehensive site audits, quality control testing and compliance verification with Good Agricultural and Collection Practices.
HYTN’s partners will now turn their attention to initiating production with a focus on high-potency cultivars. The company expects to receive the first flower shipment for GMP-certified processing in Q2 2025, with the first batch of cannabis products shipping to Germany by the end of the quarter.
According to Friday’s news release, “Germany’s medical cannabis sector is experiencing rapid growth, driven by increasing patient adoption, expanded physician prescribing and broadening pharmacy distribution.” The sector imported 20,000 kilograms of flower in Q3 2024 alone, more than double the quarterly average prior to legalization in April 2024.
The news follows HYTN’s transition into international pharmaceutical sales, including partnerships with SNDL and 4C Labs, laying the foundation for global expansion.
Leadership insights
“With global demand for GMP-certified cannabis increasing, HYTN remains committed to partnering with the most qualified cultivators to ensure seamless integration into international medical markets,” Jason Broome, HYTN Innovations’ chief operating officer, said in a statement. “We are proud to support patient access to premium medical cannabis in Germany and look forward to establishing HYTN as a preferred partner for pharmaceutical-grade cannabis in Europe.”
About HYTN Innovations
HYTN is a pharmaceutical company formulating and manufacturing products containing psychoactive and psychotropic compounds, including cannabis and psilocybe-derived tryptamines.
HYTN Innovations stock (CSE:HYTN) is up by 38.10 per cent trading at C$0.29 per share as of 10:55 am ET. The stock has added 61.11 per cent since announcing the supply agreements on March 28.
Join the discussion: Find out what everybody’s saying about this cannabis and psychedelics stock on the HYTN Innovations Inc. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image, generated by AI: Adobe Stock)
